TY - JOUR
AU - S. M. McPherson
AU - C. L. Smith
AU - L. Hall
AU - A. Q. Miguel
AU - T. Bowden
AU - A. Keever
AU - A. Schmidt
AU - K. Olson
AU - N. Rodin
AU - M. G. McDonell
AU - J. M. Roll
AU - J. LeBrun
A1 - 
AD - Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, United States; Analytics and PsychoPharmacology Laboratory (APPL), Washington State University, Spokane, WA, United States; Program of Excellence in Addiction Research (PEAR), Washington State University, Spokane, WA, United States. Electronic address: sterling.mcpherson@wsu.edu.; Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, United States; Analytics and PsychoPharmacology Laboratory (APPL), Washington State University, Spokane, WA, United States; Program of Excellence in Addiction Research (PEAR), Washington State University, Spokane, WA, United States.; Analytics and PsychoPharmacology Laboratory (APPL), Washington State University, Spokane, WA, United States; Program of Excellence in Addiction Research (PEAR), Washington State University, Spokane, WA, United States; College of Nursing, Washington State University, Spokane, WA, United States.; Ideal Option, Kennewick, WA, United States.; Analytics and PsychoPharmacology Laboratory (APPL), Washington State University, Spokane, WA, United States; Program of Excellence in Addiction Research (PEAR), Washington State University, Spokane, WA, United States; College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, United States.; Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, United States; Program of Excellence in Addiction Research (PEAR), Washington State University, Spokane, WA, United States.; Optimize Health,  5601 22nd Ave NW #200, Seattle, WA, United States.
AN - 38306822
BT - Drug Alcohol Depend
C5 - Opioids & Substance Use; HIT & Telehealth
DA - Mar 1
DO - 10.1016/j.drugalcdep.2024.111099
DP - NLM
ET - 20240122
JF - Drug Alcohol Depend
LA - eng
PY - 2024
SN - 0376-8716 (Print); 0376-8716
SP - 111099
ST - Mobile Medication Adherence Platform for Buprenorphine (MAP4BUP): A Phase I feasibility, usability and efficacy pilot randomized clinical trial
T1 - Mobile Medication Adherence Platform for Buprenorphine (MAP4BUP): A Phase I feasibility, usability and efficacy pilot randomized clinical trial
T2 - Drug Alcohol Depend
TI - Mobile Medication Adherence Platform for Buprenorphine (MAP4BUP): A Phase I feasibility, usability and efficacy pilot randomized clinical trial
U1 - Opioids & Substance Use; HIT & Telehealth
U3 - 10.1016/j.drugalcdep.2024.111099
VL - 256
VO - 0376-8716 (Print); 0376-8716
Y1 - 2024
ER -